Boston Scientific Corporation $BSX Stock Holdings Decreased by Dana Investment Advisors Inc.

Dana Investment Advisors Inc. lessened its position in Boston Scientific Corporation (NYSE:BSX) by 53.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 129,863 shares of the medical equipment provider’s stock after selling 150,709 shares during the quarter. Dana Investment Advisors Inc.’s holdings in Boston Scientific were worth $12,679,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of Boston Scientific in the second quarter worth $2,089,937,000. Edgewood Management LLC purchased a new stake in Boston Scientific in the 2nd quarter worth about $746,655,000. Parnassus Investments LLC boosted its position in Boston Scientific by 42,978.9% during the 3rd quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after acquiring an additional 6,868,459 shares during the period. Bessemer Group Inc. grew its stake in Boston Scientific by 14,391.8% during the 2nd quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock valued at $313,618,000 after acquiring an additional 2,899,653 shares in the last quarter. Finally, Jennison Associates LLC increased its holdings in shares of Boston Scientific by 133.5% in the 3rd quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock valued at $482,170,000 after purchasing an additional 2,823,744 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Trading Down 0.3%

Boston Scientific stock opened at $74.37 on Tuesday. Boston Scientific Corporation has a one year low of $72.69 and a one year high of $109.50. The company’s fifty day moving average price is $88.87 and its two-hundred day moving average price is $96.32. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The company has a market capitalization of $110.36 billion, a price-to-earnings ratio of 38.33, a PEG ratio of 1.03 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the prior year, the company posted $0.70 EPS. The firm’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on BSX. Oppenheimer decreased their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a report on Friday, January 16th. BTIG Research reissued a “buy” rating on shares of Boston Scientific in a research note on Wednesday, February 4th. Needham & Company LLC dropped their price target on shares of Boston Scientific from $121.00 to $97.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. Sanford C. Bernstein reiterated an “outperform” rating and set a $112.00 price objective on shares of Boston Scientific in a report on Friday, February 6th. Finally, Robert W. Baird lowered their target price on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $108.36.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.